Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma

M Gonzalez-Santamarta, G Quinet… - … and Disease: From …, 2020 - Springer
Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …
被引用次数：38 相关文章

Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma

M Gonzalez-Santamarta, G Quinet… - … and Disease: From …, 2020 - books.google.com
Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …

Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.

M Gonzalez-Santamarta, G Quinet… - … Medicine and Biology, 2020 - europepmc.org
Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …

Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma

M Gonzalez-Santamarta, G Quinet… - Proteostasis and …, 2020 - Springer
Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …

Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma

M Gonzalez-Santamarta, G Quinet… - PROTEOSTASIS in …, 2020 - hal.science
Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …

Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma

M Gonzalez-Santamarta, G Quinet… - Advances in …, 2020 - pubmed.ncbi.nlm.nih.gov
Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …
[PDF] hal.science

[PDF][PDF] Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma

M Gonzalez-Santamarta, G Quinet, D Reyes-Garau… - hal.science
Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …